nach oben

International Journal of Clinical Pharmacy

Erschienen in:

01.10.2012 | Research Article

Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson’s disease

verfasst von: Sabrina Schröder, Peter Martus, Per Odin, Marion Schaefer

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Background The well-being of patients with Parkinson’s disease may be improved by pharmaceutical care in community pharmacies. Objective To investigate the effects of standardised pharmaceutical care on health outcomes and quality of drug treatment in patients with Parkinson’s disease. Setting Community pharmacies in Germany. Method An open-label, multicentre, longitudinal, parallel-group study was conducted in outpatients with idiopathic Parkinson’s disease who were receiving anti-parkinsonian medication. Patients were recruited by 32 community pharmacists (pharmacy group) and local offices of the German Parkinson’s disease patients’ association (comparison group). All patients were assessed at baseline and at 8 months’ follow-up. In the intervening period, the pharmacists provided patients in the pharmacy group with standardised pharmaceutical care. Main outcome measure Mean change in symptom-related impairment of health status, assessed using the 23-item Parkinson’s Scale Total Score. Results In total 235 patients were enrolled into the study (113 pharmacy group; 122 comparison group). Between-group analysis showed that the mean changes in the primary and secondary endpoints, all 23-item Parkinson’s Scale sub-scores and the EuroQol 5-Dimension Questionnaire Index Score were significantly in favour of the pharmacy group after 8 months (p < 0.05 to p < 0.001), using a mixed model analysis. No significant changes were observed in prescribers’ guideline adherence, but there was a significant decrease in the proportion of patients receiving inappropriate drugs according to the Beers List in the pharmacy group (p < 0.01). Conclusion This study shows that significant benefits in patient health outcomes and age-related quality of drug treatment were gained when patients with Parkinson’s disease were provided with standardised pharmaceutical care in community pharmacies.

Eggert K, Deuschl G, Gasser T, Oertel WH, Arnold G, Baas H, et al. Leitlinie Parkinson-Syndrome, 2. Ausgabe. In: Leitlinien für Diagnostik und Therapie in der Neurologie. 3. überarbeitete Auflage. [Parkinson’s disease guideline. 2nd edn. In: Guidelines for diagnosis and therapy in neurology. 3rd revised edn.]. Stuttgart: Georg Thieme Verlag; 2005, ISBN:[3-13-132413-9]. In German.

Visser M, Verbaan D, van Rooden S, Marinus J, van Hilten J, Stiggelbout A. A longitudinal evaluation of health-related quality of life of patients with Parkinson’s disease. Value Health. 2009;12(2):392–6.PubMedCrossRef

Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL. Linking clinical variables to health-related quality of life in Parkinson’s disease. Parkinsonism Relat Disord. 2002;8(3):199–209.PubMedCrossRef

Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson’s disease? J Neurol. 2002;249(4):419–23.PubMedCrossRef

Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Limitations of current Parkinson’s disease therapy. Ann Neurol. 2003;53 Suppl 3:S3–S12; discussion S12–5.

Leoni O, Martignoni E, Cosentino M, Michielotto D, Calandrella D, Zangaglia R, et al. Drug prescribing patterns in Parkinson’s disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf. 2002;11(2):149–57.PubMedCrossRef

Schröder S, Zöllner YF, Schaefer M. Drug related problems with Antiparkinsonian agents: consumer Internet reports versus published data. Pharmacoepidemiol Drug Saf. 2007;16(10):1161–6.PubMedCrossRef

Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–43.PubMed

van Mil JWF, Schulz M. A review of pharmaceutical care in community pharmacy in Europe. Harv Health Policy Rev. 2006;7(1):155–68.

10.

Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond CM, et al. Effect of outpatient pharmacists’ non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev. 2010;7.

11.

Mynors G, Jenkinson C, MacNeill V, Balcon R. A pilot evaluation of specialist community pharmacy services for patients with Parkinson’s disease. Pharm J. 2007;278(7456):709–12.

12.

Schaefer M, Schulz M. Manuale zur Pharmazeutischen Betreuung—Band 1: Grundlagen der Pharmazeutischen Betreuung [Manuals on pharmaceutical care—volume 1: foundations of pharmaceutical care]. Govi-Verlag; 2000. ISBN:978-3-7741-0844-8. In German.

13.

Barmer Ersatzkasse (BEK), Deutschen Apothekerverband e.V. (DAV). Vereinbarung zwischen der Barmer Ersatzkasse (BEK) und dem Deutschen Apothekerverband e.V. (DAV) zur Intensivierung der Kooperation bei der qualitätsorientierten Versorgung der Versicherten [Agreement between Barmer Ersatzkasse (BEK) and the German Pharmacists’ Association (DAV) to intensify cooperation in the quality-oriented care of insured patients]. 2004. In German.

14.

Schröder S, Martus P, Odin P, Schaefer M. Drug-related problems in Parkinson’s disease: the role of community pharmacists in primary care. Int J Clin Pharm. 2011;33(4):674–82.PubMedCrossRef

15.

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–4.PubMedCrossRef

16.

World Medical Association (WMA). Declaration of Helsinki. Ethical principles for medical research involving human subjects. 52nd WMA General Assembly, Edinburgh, Scotland, Oct 2000 (updated at 53rd WMA General Assembly, Washington, DC, USA, Oct 2002).

17.

Apothekenbetriebsordnung (ApBetrO). Verordnung über den Betrieb von Apotheken [Ordinance on the operation of pharmacies]. BGBl. 1995;51:1195; amended in BGBI. 2005;34:1645. In German.

18.

Arzneimittelgesetz (AMG). Gesetz über den Verkehr mit Arzneimitteln [Law on the marketing of drugs]. BGBl. 2005;73:3394. In German.

19.

Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427–42.PubMedCrossRef

20.

Martus P. Entwicklung einfacher Scores für Dimensionen der Symptomschwere bei Morbus Parkinson auf Basis der Faktorscores des PS-23 Fragebogeninstruments [Development of simple scores for dimensions of symptom severity in Parkinson’s disease based on the factor scores of the PS-23 questionnaire instrument]. Technical report from the Charité Centrum für Therapieforschung [report on the internet]. 2010. Cited June 2012. Available from: http://www.medizin.uni-tuebingen.de/uktmedia/Einrichtungen/Institute/Institut+fuer+Medizinische+Biometrie/PDF_Archiv/Martus+report+PS_23.pdf. In German.

21.

Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: development and validation of a short-form Parkinson’s disease questionnaire. Psychol Health. 1997;12(6):805–14.CrossRef

22.

The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRef

23.

Brooks R, Rabin R, de Charro F. The measurement and valuation of health status using EQ-5D: a European perspective. Boston: Kluwer Academic Publishers; 2003. p. 324. ISBN:1-4020-1214-4.

24.

Schwalbe O, Freiberg I, Kloft C. Die Beers-Liste: Ein Instrument zur Optimierung der Arzneimitteltherapie geriatrischer Patienten [The Beers criteria: an instrument to optimise the pharmacotherapy of geriatric patients]. Med Monatsschr Pharm. 2007;30(7):244–8.PubMed

25.

Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med. 1991;151(9):1825–32.PubMedCrossRef

26.

Schröder S, Kuessner D, Arnold G, Zöllner Y, Jones E, Schaefer M. Do neurologists in Germany adhere to the national Parkinson’s disease guideline? Neuropsychiatr Dis Treat. 2011;7:103–10.PubMed

27.

Liang MH, Fossel AH, Larson MG. Comparisons of five health status instruments for orthopedic evaluation. Med Care. 1990;28(7):632–42.PubMedCrossRef

28.

Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;21(7):916–23.PubMedCrossRef

29.

Lee MA, Prentice WM, Hildreth AJ, Walker RW. Measuring symptom load in idiopathic Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(5):284–9.PubMedCrossRef

30.

Roughead EE, Semple SJ, Vitry AI. Pharmaceutical care services: a systematic review of published studies, 1990 to 2003, examining effectiveness in improving patient outcomes. Int J Pharm Pract. 2005;13(1):53–70.CrossRef

31.

Scottish Intercollegiate Guidelines Network (SIGN). SIGN 50: a guideline developer’s handbook [book on the internet]. 2008. Cited Oct 2011. Available from: http://www.sign.ac.uk/guidelines/fulltext/50/annexb.html.

32.

Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother. 2007;41(10):1569–78.PubMedCrossRef

33.

Machado M, Nassor N, Bajcar JM, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother. 2008;42(9):1195–207.PubMedCrossRef

34.

Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging. 2006;23(9):693–721.PubMedCrossRef

35.

Harrison JE, Preston S, Blunt SB. Measuring symptom change in patients with Parkinson’s disease. Age Ageing. 2000;29(1):41–5.PubMedCrossRef

36.

Reuther M, Spottke EA, Klotsche J, Riedel O, Peter H, Berger K, et al. Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism Relat Disord. 2007;13(2):108–14.PubMedCrossRef

37.

Schrag A, Spottke A, Quinn NP, Dodel R. Comparative responsiveness of Parkinson’s disease scales to change over time. Mov Disord. 2009;24(6):813–8.PubMedCrossRef

38.

Luo N, Ng WY, Lau PN, Au WL, Tan LC. Responsiveness of the EQ-5D and 8-item Parkinson’s Disease Questionnaire (PDQ-8) in a 4-year follow-up study. Qual Life Res. 2010;19(4):565–9.PubMedCrossRef

39.

Kheir NM, van Mil JW, Shaw JP, Sheridan JL. Health-related quality of life measurement in pharmaceutical care. Targeting an outcome that matters. Pharm World Sci. 2004;26(3):125–8.PubMedCrossRef

40.

Jano E, Aparasu RR. Healthcare outcomes associated with beers’ criteria: a systematic review. Ann Pharmacother. 2007;41(3):438–47.PubMedCrossRef

41.

Al-Momany NH, Al-Bakri AG, Makahleh ZM, Wazaify MM. Adherence to international antimicrobial prophylaxis guidelines in cardiac surgery: a Jordanian study demonstrates need for quality improvement. J Manag Care Pharm. 2009;15(3):262–71.PubMed

42.

Bond CM, Fish A, Porteous TH, Reid JP, Scott A, Antonazzo E. A randomised controlled trial of the effects of note-based medication review by community pharmacists on prescribing of cardiovascular drugs in general practice. Int J Pharm Pract. 2007;15(1):39–46.CrossRef

Titel: Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson’s disease
verfasst von: Sabrina Schröder
Peter Martus
Per Odin
Marion Schaefer
Publikationsdatum: 01.10.2012
Verlag: Springer Netherlands
Erschienen in: International Journal of Clinical Pharmacy / Ausgabe 5/2012
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-012-9672-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2012

Epidemiology and cost analysis of pharmacist interventions at Ghent University Hospital

The role of clinical pharmacist to improve medication administration through enteral feeding tubes by nurses

Retraction Note: Use of antidepressants and the risk of type 2 diabetes mellitus: a nested case–control study

Preventable drug-related morbidity in community pharmacy: commentary on the implications for practice and policy of a novel intervention

Difference of antihypertensive prescribing between office- and hospital-based clinics in Taiwan

A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and re-challenge